Skip to Content
  • Previous Rank28
  • Revenues ($M)119,569
  • Revenue Percent Change34.1%
  • Profits ($M)277
  • Profits Percent Change-36.3%
  • Market Value (as of March 31, 2015)24,963

AmerisourceBergen, one of the largest global pharmaceutical distribution and sourcing services companies, has been flying high since initiating a partnership with Walgreens Boots Alliance in 2013. The deal was fully implemented in the first quarter of 2015 and given the distributor a healthy profit and revenue boost with even more gains ahead. Full year earnings are expected to be up 16% for fiscal 2015 and up 14% in 2016. As a result of the deal, AmerisourceBergen and Walgreens are able to pool their generic drug buying to get even better discounts from manufacturers—a big boost to their bottom line. AmerisourceBergen is adding even more to its growth equation, venturing into the fast-growing animal health industry with its January purchase of MWI Veterinary Supply. MWI sells everything from pharmaceuticals for pets to pet food and equipment. U.S. veterinary spending on pets has grown at about 6% per year over the past seven years—and it’s an industry that isn’t privy to government pricing pressure.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Steven H. Collis
Industry
Wholesalers: Health Care
Sector
Wholesalers
HQ Location
Chesterbrook, PA
Websitehttp://www.amerisourcebergen.com
Years on List21

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)119,56934.1%
Profits ($M)277-36.3%
Total Stockholder Equity1,957-
Employees13,500-
Market Value (as of March 31, 2015)24,963-

Profit Ratios

Profit as % of Revenues0.2%
Profits as % of Assets1.3%
Profits as % of Stockholder Equity14.1%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)1.17
EPS % Change (from 2013)-36.4%
EPS % Change (5 year annual rate)-6.8%
EPS % Change (10 year annual rate)1.4%

Total Return

Total Return to Investors (2014)29.9%
Total Return to Investors (5 year, annualized)29.9%
Total Return to Investors (10 year, annualized)21.4%